2. Ongoing clinical trials of targeted therapy.

Title	NCT trial No.	Drug (s) tested	Sample size	Primary end point	Phase
DLT, dose-limiting toxicity; OS, overall survival; AE, adverse events/effect; SAE, serious adverse event; TRAE, treatment emergent adverse event; ECOG, Eastern Cooperative Oncology Group; ORR, objective response rate; PFS, progression-free survival; PD, progressive disease; MTD, maximum tolerated dose; mFOLFOX6 treatment includes oxaliplatin, leucovorin, fluorouracil; CAPOX contains capecitabine and oxaliplatin.
A phase 2, open-label, randomized study to assess the antitumor activity and safety of zolbetuximab (IMAB362) in combination with nab-paclitaxel and gemcitabine (Nab-P+GEM) as first line treatment in subjects with claudin 18.2 (CLDN18.2) positive, metastatic pancreatic adenocarcinoma	NCT03816163	Zolbetuximab + nab-paclitaxel + gemcitabine	141	DLT, OS, AEs (SAE, TRAEs), ECOG	2
A phase 2 study of zolbetuximab (IMAB362) as monotherapy or in combination with mFOLFOX6 in subjects with metastatic or locally advanced unresectable gastric or gastroesophageal junction (GEJ) adenocarcinoma whose tumors have high or intermediate claudin (CLDN) 18.2 expression	NCT03505320	Zolbetuximab + mFOLFOX6	102	ORR	2
A phase 3, global, multi-left, double-blind, randomized, efficacy study of zolbetuximab plus mFOLFOX6 compared with placebo plus mFOLFOX6 as first-line treatment of subjects with claudin 18.2-positive, HER2-negative, locally advanced unresectable or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma	NCT03504397	Zolbetuximab + mFOLFOX6	550	PFS	3
A phase 3, global, multi-left, double-blind, randomized, efficacy study of zolbetuximab (IMAB362) plus CAPOX compared with placebo plus CAPOX as first-line treatment of subjects with claudin (CLDN) 18.2-positive, HER2-negative, locally advanced unresectable or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma	NCT03653507	Zolbetuximab + CAPOX	500	PFS, PD	3
An open label, dose escalating/dose regimen finding clinical study to evaluate the safety, efficacy, and cytokinetics of autologous humanized anti-claudin 18.2 chimeric antigen receptor T cell in advanced solid tumor subjects	NCT03874897	CAR-CLDN18.2 T-cells	15	DLT, MTD	1
Clinical study of redirected autologous T cells with a claudin18.2-targeted chimeric antigen receptor in patients with advanced gastric adenocarcinoma and pancreatic adenocarcinoma	NCT03159819	CAR-CLDN18.2 T-cells	24	Safety, tolerability	−
A phase 1 study of LCAR-C182A cells in the treatment of advanced gastric cancer and pancreatic ductal adenocarcinoma	NCT03890198	CAR-CLDN18.2 T-cells LCAR-C182C Cells	18	AEs, transgene levels and cell concentration of LCAR-C82 CAR-T Cells, cytokine concentrations	1